H
H. Marijke van den Berg
Researcher at Utrecht University
Publications - 46
Citations - 4116
H. Marijke van den Berg is an academic researcher from Utrecht University. The author has contributed to research in topics: Clotting factor & Haemophilia. The author has an hindex of 25, co-authored 46 publications receiving 3209 citations.
Papers
More filters
Journal ArticleDOI
WFH Guidelines for the Management of Hemophilia, 3rd edition
Alok Srivastava,Elena Santagostino,Alison Dougall,Steve Kitchen,Megan Sutherland,Steven W. Pipe,Manuel Carcao,Johnny Mahlangu,Margaret V. Ragni,Jerzy Windyga,Adolfo Llinás,Nicholas J. Goddard,Richa Mohan,Pradeep M. Poonnoose,Brian M. Feldman,Sandra Zelman Lewis,H. Marijke van den Berg,Glenn F. Pierce +17 more
TL;DR: The WFH Guidelines for the Management of Hemophilia panelists and co-authors thank the panelists for their time and share their views on how to better understand and treat hemophilia.
Journal ArticleDOI
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
TL;DR: The findings suggest that the previously reported associated between an early age at first exposure and the risk of inhibitor development is largely explained by early, intensive treatment, and early, regular prophylaxis may protect patients with hemophilia against the development of inhibitors.
Journal ArticleDOI
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
Samantha C. Gouw,Johanna G. van der Bom,Rolf Ljung,Carmen Escuriola,Ana Rosa Cid,Ségolène Claeyssens-Donadel,Christel Van Geet,Gili Kenet,Anne Mäkipernaa,Angelo Claudio Molinari,Wolfgang Muntean,Rainer Kobelt,George E Rivard,E. Santagostino,Angela Thomas,H. Marijke van den Berg +15 more
TL;DR: Recombinant and plasma-derived factor VIII products conferred similar risks of inhibitor development, and the content of von Willebrand factor in the products and switching among products were not associated with the risk of inhibitors development.
Journal ArticleDOI
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
Samantha C. Gouw,Samantha C. Gouw,H. Marijke van den Berg,Johannes Oldenburg,Jan Astermark,Philip G. de Groot,Maurizio Margaglione,Arthur R. Thompson,Waander L. van Heerde,Jorien Boekhorst,Connie H. Miller,Saskia le Cessie,Johanna G. van der Bom +12 more
TL;DR: The primary outcome was inhibitor development and the secondary outcome was high-titer-inhibitor development, and the relative risks for developing high titer inhibitors were similar.
Journal ArticleDOI
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
Samantha C. Gouw,H. Marijke van den Berg,Krista Fischer,Guenter Auerswald,Manuel Carcao,Elizabeth Chalmers,Hervé Chambost,Karin Kurnik,Ri Liesner,Pia Petrini,Helen Platokouki,Carmen Altisent,Johannes Oldenburg,Beatrice Nolan,Rosario Perez Garrido,M Elisa Mancuso,Anne Rafowicz,Michael Williams,Niels Clausen,Rutger A. Middelburg,Rolf Ljung,Johanna G. van der Bom +21 more
TL;DR: It is suggested that in previously untreated patients with severe hemophilia A, high-dosed intensive FVIII treatment increases inhibitor risk and prophylactic FV III treatment decreases inhibitor risk, especially in patients with low-risk F8 mutations.